Edesa Biotech assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech (EDSA) with a Buy rating and $5 price target Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company’s lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.